JP2024512418A - 新規な免疫活性インターロイキン２アナログ結合体及びその製造方法 - Google Patents

新規な免疫活性インターロイキン２アナログ結合体及びその製造方法 Download PDF

Info

Publication number
JP2024512418A
JP2024512418A JP2023555563A JP2023555563A JP2024512418A JP 2024512418 A JP2024512418 A JP 2024512418A JP 2023555563 A JP2023555563 A JP 2023555563A JP 2023555563 A JP2023555563 A JP 2023555563A JP 2024512418 A JP2024512418 A JP 2024512418A
Authority
JP
Japan
Prior art keywords
interleukin
amino acid
amino acids
analog
deleted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512418A5 (https=
JPWO2022211537A5 (https=
Inventor
ヨンホ ホ
ウリム オ
ダヒョン パク
ジンヨン キム
ジュンソプ パク
ユヨン キム
アラム リ
サンユン キム
Original Assignee
ハンミ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンミ ファーマシューティカル カンパニー リミテッド filed Critical ハンミ ファーマシューティカル カンパニー リミテッド
Publication of JP2024512418A publication Critical patent/JP2024512418A/ja
Publication of JP2024512418A5 publication Critical patent/JP2024512418A5/ja
Publication of JPWO2022211537A5 publication Critical patent/JPWO2022211537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023555563A 2021-03-31 2022-03-31 新規な免疫活性インターロイキン２アナログ結合体及びその製造方法 Pending JP2024512418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210042305 2021-03-31
KR10-2021-0042305 2021-03-31
PCT/KR2022/004620 WO2022211537A1 (ko) 2021-03-31 2022-03-31 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법

Publications (3)

Publication Number Publication Date
JP2024512418A true JP2024512418A (ja) 2024-03-19
JP2024512418A5 JP2024512418A5 (https=) 2025-04-10
JPWO2022211537A5 JPWO2022211537A5 (https=) 2025-04-10

Family

ID=83459706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555563A Pending JP2024512418A (ja) 2021-03-31 2022-03-31 新規な免疫活性インターロイキン２アナログ結合体及びその製造方法

Country Status (15)

Country Link
US (1) US12599675B2 (https=)
EP (1) EP4316528A4 (https=)
JP (1) JP2024512418A (https=)
KR (2) KR102680146B1 (https=)
CN (1) CN116916969A (https=)
AR (1) AR125263A1 (https=)
AU (1) AU2022209248B2 (https=)
BR (1) BR112023018530A2 (https=)
CA (1) CA3205058C (https=)
CL (1) CL2023002504A1 (https=)
IL (1) IL304365B2 (https=)
MX (1) MX2023010926A (https=)
PE (1) PE20250672A1 (https=)
WO (1) WO2022211537A1 (https=)
ZA (1) ZA202307219B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022009123A1 (en) * 2020-07-09 2022-01-13 Eutilex Co., Ltd. Il-2 variants
AU2023408268A1 (en) 2022-12-23 2025-07-10 Hanmi Pharm. Co., Ltd. Formulations comprising immune stimulating IL-2 analog conjugates
KR20240137492A (ko) * 2023-03-07 2024-09-20 한미약품 주식회사 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법
JP2026509259A (ja) * 2023-03-07 2026-03-17 ハンミ ファーマシューティカル カンパニー リミテッド インターロイキン２アナログ又はその結合体を含む癌予防又は治療用薬学的組成物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528347A (ja) * 2003-04-03 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 延長された生体内半減期を有するｐｅｇ−生理活性ポリペプチド同種二量体結合体及びその製造方法
JP2014506793A (ja) * 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−２ポリペプチド
JP2017506264A (ja) * 2014-02-21 2017-03-02 ネクター セラピューティクス （インディア） プライベート リミテッド 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬
JP2017527272A (ja) * 2014-07-21 2017-09-21 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
JP2018512151A (ja) * 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質
WO2019185705A1 (en) * 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
JP2019536734A (ja) * 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
WO2020020783A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20200078312A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
WO2020260270A1 (en) * 2019-06-24 2020-12-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2021030633A1 (en) * 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP3943101A1 (en) 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
WO2017052329A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
US11077172B2 (en) * 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US20200299349A1 (en) * 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528347A (ja) * 2003-04-03 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 延長された生体内半減期を有するｐｅｇ−生理活性ポリペプチド同種二量体結合体及びその製造方法
JP2014506793A (ja) * 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−２ポリペプチド
JP2017506264A (ja) * 2014-02-21 2017-03-02 ネクター セラピューティクス （インディア） プライベート リミテッド 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬
JP2017527272A (ja) * 2014-07-21 2017-09-21 デリニア， インコーポレイテッド 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
JP2018512151A (ja) * 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質
JP2019536734A (ja) * 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
WO2019185705A1 (en) * 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
WO2020020783A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20200078312A (ko) * 2018-12-21 2020-07-01 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
WO2020260270A1 (en) * 2019-06-24 2020-12-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2021030633A1 (en) * 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists

Also Published As

Publication number Publication date
CA3205058C (en) 2024-04-09
ZA202307219B (en) 2024-10-30
PE20250672A1 (es) 2025-03-04
KR20240099117A (ko) 2024-06-28
EP4316528A4 (en) 2026-03-11
CA3205058A1 (en) 2022-10-26
AU2022209248B2 (en) 2023-06-29
CN116916969A (zh) 2023-10-20
US20240009317A1 (en) 2024-01-11
AR125263A1 (es) 2023-06-28
EP4316528A1 (en) 2024-02-07
CL2023002504A1 (es) 2024-01-26
KR20220136285A (ko) 2022-10-07
IL304365A (en) 2023-09-01
AU2022209248A1 (en) 2022-10-20
IL304365B1 (en) 2024-12-01
IL304365B2 (en) 2025-04-01
MX2023010926A (es) 2023-09-27
KR102680146B1 (ko) 2024-07-04
WO2022211537A1 (ko) 2022-10-06
US12599675B2 (en) 2026-04-14
BR112023018530A2 (pt) 2023-10-10
TW202304521A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
JP2024512418A (ja) 新規な免疫活性インターロイキン２アナログ結合体及びその製造方法
EP3896085A1 (en) Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
TW201927806A (zh) Ｇｌｐ－２衍生物之長效接合物
KR20220092442A (ko) 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
JP2023538236A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
CN110536899A (zh) 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
HK40100172A (en) Novel immunoactive interleukin 2 analog conjugate and method for preparing same
EP4678180A1 (en) Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof
EA049515B1 (ru) Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения
EP4678181A1 (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
JP2024527220A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む組み合わせ物の治療学的用途
KR20220041766A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
HK40130618A (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
EP4512414A1 (en) Combination therapy of glp-2 with insulinotropic peptide, tnf? inhibitor or both for preventing or treating intestinal diseases
JP2023546384A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の呼吸器感染疾患の後遺症の治療用途
KR20240102886A (ko) 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260226